Sirnaomics Ltd. (2257) AI Stock Analysis

• Market Cap: HK$831.69M
• Dividend Yield: N/A
• Average Volume (3M): 472.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: N/A
• EPS Growth: 83.89%
• Country: HK
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 106,217,834
• 10 Day Avg. Volume: 448,290
• 30 Day Avg. Volume: 472,275
• PEG Ratio: 0.02
• Price to Book (P/B): -20.53
• Price to Sales (P/S): 19.40
• P/FCF Ratio: -1.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -17.2
• Revenue Forecast (FY): N/A

• Rating: 40 Neutral
• Price Target: HK$7.50 ▼(-40.57% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by significant losses and a precarious balance sheet. Technical analysis indicates a bearish trend, further weighing on the score. The valuation is also unfavorable due to the negative P/E ratio and absence of dividends, which may limit investor interest.

Sirnaomics Ltd. Business Overview & Revenue Model

Company Description

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Sirnaomics generates revenue primarily through a combination of product sales, research grants, and collaborations with other pharmaceutical companies. The company's revenue model is driven by the successful development and commercialization of its RNAi therapeutics, which may include upfront payments, milestone payments, and royalties from licensing agreements. Additionally, Sirnaomics may receive funding from government and private research grants that support its innovative research initiatives. Strategic partnerships with larger pharmaceutical firms can also provide significant financial backing and resources, enabling Sirnaomics to accelerate its drug development processes and expand its market presence.

Sirnaomics Ltd. Financial Statement Overview

Summary

Sirnaomics Ltd. faces significant financial challenges with persistent operating losses and a weak balance sheet characterized by negative equity. Despite some revenue growth and improvements in free cash flow, the company remains unprofitable with high cash burn, raising concerns about its ability to sustain operations without further financing.

Income Statement

The company's income statement reveals ongoing challenges in profitability and revenue growth. Despite an increase in revenue from the previous year, the net profit margin remains deeply negative at -289.0% for 2024, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Although the gross profit margin is positive at 67.4%, it is insufficient to offset the high operating expenses.

Balance Sheet

The balance sheet indicates a precarious financial position with negative stockholders' equity, signaling insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, but the company has managed to maintain a relatively low total debt level. The equity ratio is negative, reflecting a higher liability level than assets, which poses a financial stability risk.

Cash Flow

The cash flow statement shows a significant negative free cash flow, indicating cash burn exceeding income. The operating cash flow to net income ratio is negative, highlighting cash outflows in operations. However, there is a noticeable improvement in free cash flow, which grew positively from 2023 to 2024, suggesting some progress towards better cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	949.00K	1.78M	397.00K	705.00K	0.00	0.00
Gross Profit	370.00K	1.20M	397.00K	705.00K	-12.67M	0.00
EBITDA	-15.48M	-31.12M	-72.36M	-89.02M	-1.66B	-19.27M
Net Income	-14.02M	-51.38M	-78.69M	-88.30M	-1.66B	-43.77M
Balance Sheet
Total Assets	21.30M	28.33M	75.79M	163.93M	240.65M	110.18M
Cash, Cash Equivalents and Short-Term Investments	6.87M	11.77M	43.93M	105.23M	211.99M	103.12M
Total Debt	7.21M	8.06M	8.85M	10.76M	7.04M	91.87M
Total Liabilities	40.40M	44.33M	51.33M	52.37M	30.36M	204.36M
Stockholders Equity	-5.12M	-1.68M	40.20M	122.01M	211.62M	-94.43M
Cash Flow
Free Cash Flow	-9.26M	-19.84M	-72.03M	-107.54M	-62.85M	-21.15M
Operating Cash Flow	-9.26M	-19.73M	-70.29M	-88.71M	-56.97M	-19.00M
Investing Cash Flow	1.94M	2.14M	-5.35M	-32.61M	-6.04M	8.39M
Financing Cash Flow	6.53M	5.82M	-5.61M	15.89M	170.96M	100.37M

Sirnaomics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Negative. The current price of 12.62 is above the 20-day moving average (MA) of 8.86, above the 50-day MA of 12.58, and above the 200-day MA of 7.00, indicating a neutral trend. The MACD of -1.16 indicates Negative momentum. The RSI at 31.73 is Neutral, neither overbought nor oversold. The STOCH value of 25.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2257.

Sirnaomics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	52 Neutral	HK$1.48B	181.90	0.99%	―	9.41%	-32.69%
2197	52 Neutral	HK$2.80B	-2.69	―	―	79.98%	-3.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3681	45 Neutral	HK$2.21B	―	-55.33%	―	-100.00%	30.68%
2616	42 Neutral	HK$8.81B	-19.44	-95.84%	―	-55.64%	-158.67%
6628	41 Neutral	HK$1.16B	―	-34.18%	―	-57.84%	24.58%
2257	40 Neutral	HK$831.69M	―	―	―	―	83.89%

Sirnaomics Ltd. Corporate Events

Sirnaomics Ltd. Successfully Implements Remedial Actions for Internal Control

Sirnaomics Ltd. has announced the completion of its remedial actions to address internal control weaknesses and deficiencies, as identified in a recent internal control review. The company engaged PAL Advisory Limited to assess the effectiveness of these actions, particularly focusing on business communication standards. The review confirmed that the company’s measures, including mandatory training and policy updates, have adequately addressed the issues, thereby enhancing data security and compliance within the organization.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Allocates HK$206 Million for RNA Therapeutics Development

Sirnaomics Ltd. has announced a supplemental update on the allocation of net proceeds from its recent share subscription, amounting to approximately HK$206.0 million. The funds will primarily be used to advance the development and commercialization of its key drug candidates, including STP705 and STP122G, with a strategic focus on completing clinical trials by the end of 2027. This financial move is expected to bolster the company’s position in the biotech industry and support its ongoing efforts to enrich its product pipeline, ultimately benefiting shareholders.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Announces New Share Subscription to Boost Financial Standing

Sirnaomics Ltd. announced the subscription of 17,352,421 new shares under a general mandate, priced at HK$12.00 per share. This move, which does not require shareholder approval, represents approximately 16.50% of the company’s existing issued share capital and aims to enhance the company’s financial position, potentially impacting its market presence and stakeholder interests.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Announces Board Reshuffle with New Appointment

Sirnaomics Ltd. has announced significant changes in its board of directors, including the resignation of Ms. Monin Ung as an independent non-executive director and the appointment of Dr. Yin Huijun as a non-executive director. These changes reflect a strategic shift in the company’s leadership, potentially impacting its governance and operational focus. Dr. Yin’s extensive experience in the biotechnology sector is expected to contribute to the company’s growth and strengthen its position in the industry.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Releases Interim Results for First Half of 2025

Sirnaomics Ltd. has announced its unaudited condensed consolidated interim results for the six months ending June 30, 2025. The interim results, which comply with the Hong Kong Stock Exchange’s listing rules, will be available on the company’s website and dispatched to shareholders in early September 2025. This announcement reflects the company’s commitment to transparency and regulatory compliance, potentially impacting its market position and stakeholder confidence.

The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.

Sirnaomics Ltd. Schedules Board Meeting to Review Interim Results

Sirnaomics Ltd. has announced that its board of directors will convene on August 28, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.